1. Search Result
Search Result
Results for "

epidermal

" in MedChemExpress (MCE) Product Catalog:

130

Inhibitors & Agonists

2

Screening Libraries

2

Biochemical Assay Reagents

11

Peptides

3

Inhibitory Antibodies

15

Natural
Products

53

Recombinant Proteins

5

Isotope-Labeled Compounds

8

Antibodies

6

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132259

    ABT-414

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used for cancer research .
    Depatuxizumab mafodotin
  • HY-148949

    Kallikrein Others
    Kallikrein 5-IN-2 (compound 21) is a selective Kallikrein KLK5 inhibitor (pIC50=7.1). KLK5 inhibition may normalise epidermal shedding and reduce the associated inflammation and itching .
    Kallikrein 5-IN-2
  • HY-113008B

    (E)-Urocanic acid; trans-UCA

    Endogenous Metabolite Inflammation/Immunology
    trans-urocanic acid (trans-UCA), a natural epidermal constituent, inhibits human natural killer cell (NK) activity in vitro. trans-urocanic acid is active in regulating an immune function .
    trans-Urocanic acid
  • HY-164159

    Reactive Oxygen Species Inflammation/Immunology
    α-Glucosylrutin is a potent antioxidant with free radical scavenging activity. Due to its high epidermal bioavailability, α-Glucosylrutin can be used in the study of skin aging .
    α-Glucosylrutin
  • HY-18963

    RG-14355

    EGFR Cancer
    Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .
    Lavendustin A
  • HY-N0128
    Sclareol
    2 Publications Verification

    Apoptosis Cancer
    Sclareol is isolated from Salvia sclarea with anticarcinogenic activity. Sclareol shows strong cytotoxic activity against mouse leukemia?(P-388), human epidermal?carcinoma?(KB) cells and human?leukemia?cell lines. Sclareol induces cell apoptosis .
    Sclareol
  • HY-P1085

    EGFR Cancer
    Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid peptide fragment derived from positions 985-996 in epidermal growth factor receptor (EGFR) .
    Epidermal Growth Factor Receptor Peptide (985-996)
  • HY-NP145

    Biochemical Assay Reagents Metabolic Disease
    Epidermal Growth Factor, murine submaxillary gland is a biologically active polypeptide isolated from mouse submandibular gland. Epidermal Growth Factor, murine submaxillary gland is a mitogen that stimulates the growth of epithelial cells, fibroblasts and glial cells under various experimental conditions .
    Epidermal Growth Factor,murine submaxillary gland
  • HY-E70439

    TG3; TGase 3

    Biochemical Assay Reagents Others
    Human epidermal transglutaminase (TG3) is a transferase. Enzymes have high catalytic efficiency, high specificity, and mild operating conditions. It can be applied in industries such as pharmaceuticals, industrial production, food manufacturing, and aquaculture .
    Human epidermal transglutaminase
  • HY-N1658

    Tyrosinase Others
    2,3-Dihydroisoginkgetin, a biflavonoid, is a inhibitor of Tyrosinase, with 36.84% inhibition at 0.1 mM. 2,3-Dihydroisoginkgetin shows less toxicity in HEMn (human epidermal melanocytes) cells, with an IC50 of 86.16 μM .
    2,3-Dihydroisoginkgetin
  • HY-18963R

    RG-14355 (Standard)

    EGFR Cancer
    Lavendustin A (Standard) is the analytical standard of Lavendustin A. This product is intended for research and analytical applications. Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis[1][2].
    Lavendustin A (Standard)
  • HY-13314A

    XL-647 tosylate; EXEL-7647 tosylate; KD-019(tosylate)

    EGFR VEGFR Src Cancer
    Tesevatinib (XL-647) tosylate is an orally available, blood-brain barrier-penetrant inhibitor of the epidermal growth factor receptor (EGFR). Tesevatinib tosylate significantly reduces cellular viability, with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Tesevatinib tosylate also inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM). Tesevatinib tosylate can inhibit tumor proliferation and exhibits antitumor activity .
    Tesevatinib tosylate
  • HY-138298A
    Trastuzumab deruxtecan
    1 Publications Verification

    DS-8201; DS-8201a

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan
  • HY-100923

    PKA 5-HT Receptor EGFR Neurological Disease
    H-9 Dihydrochloride is a PKA (protein kinase) inhibitor. H-9 Dihydrochloride (10 μM) significantly reduces the excitatory response to 5-HT. H-9 Dihydrochloride also has a direct effect on pharyngeal activity. H-9 Dihydrochloride inhibits signal-transduction and cell growth in EGF (epidermal growth factor)-dependent epithelial cell lines .
    H-9 Dihydrochloride
  • HY-138298
    Trastuzumab deruxtecan (solution)
    1 Publications Verification

    DS-8201 (solution); DS-8201a (solution)

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan (solution)
  • HY-117081

    Endogenous Metabolite Others
    C30(ω-hydroxy) Ceramide (d18:1/30:0), a sphingolipid, is an epidermis-specifically vital component of the water barrier in mammalian skin. C30(ω-hydroxy) Ceramide (d18:1/30:0) is expressed in epidermal keratinocytes and male germ cells during their differentiation and maturation. C30(ω-hydroxy) Ceramide (d18:1/30:0) deficiency in the epiderm of Elovl4 deletion or mutation mice .
    C30(ω-hydroxy) Ceramide (d18:1/30:0)
  • HY-113509
    Lipoxin A4
    1 Publications Verification

    LXA4

    Interleukin Related Endogenous Metabolite Inflammation/Immunology
    Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties . Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways . Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM .
    Lipoxin A4
  • HY-111378A

    Casein Kinase Others
    Casein Kinase II Inhibitor IV Hydrochloride is a small-molecule inducer of epidermal keratinocyte differentiation.
    Casein Kinase II Inhibitor IV hydrochloride
  • HY-164718

    EGFR Cancer
    Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity .
    Sevabertinib
  • HY-144680

    ZL-2313

    EGFR Cancer
    BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC) .
    BLU-945
  • HY-169755

    EGFR Cancer
    Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor with IC50 and Ki values are 375 and 123 μM, respectively .
    Tyrphostin 63
  • HY-150782

    EGFR Cancer
    UNC-CA359 is a potent epidermal growth factor receptor (EGFR) inhibitor, with an IC50 value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research . UNC-CA359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    UNC-CA359
  • HY-160613

    EGFR Cancer
    EGFR/HER2-IN-11 (compound 20) is an orally active dual inhibitor for human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), with IC50s of 7.7 and 22 nM, respectively. EGFR/HER2-IN-11 exhibits antitumor efficacy and inhibits proliferation against cancer cells BT-474 with GI50 of 601 nM .
    EGFR/HER2-IN-11
  • HY-122347

    GW823296

    Neurokinin Receptor Neurological Disease
    Orvepitant (GW823296) is a compound with the ability to inhibit pruritus induced by cancer epidermal growth factor receptor inhibitor (EGFRI) and is a neurokinin-1 receptor antagonist.
    Orvepitant
  • HY-172160

    EGFR Cancer
    HER2-IN-21 (compound 657994) is a human epidermal growth factor receptor 2 (HER2) inhibitor, with an IC50 of 3.85 μM .
    HER2-IN-21
  • HY-12806

    EGFR Cancer
    AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has a pIC50 value of 8.194 .
    AG1557
  • HY-115716

    EGFR Cancer
    EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance.
    EGFR-IN-17
  • HY-131864

    EGFR PROTACs Cancer
    SJF-1528 is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells. SJF-1528 also degrades HER2 (Pink: ligand for target protein (HY-159047); Black: linker Tos-PEG2-CH2-Boc (HY-130532); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .
    SJF-1528
  • HY-15772S3

    asandeutertinibum; Osimertinib-d3; AZD-9291-d3

    EGFR Cancer
    Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with antineoplastic effect .
    Asandeutertinib
  • HY-125407

    N-Palmitoyl serinol

    Cannabinoid Receptor Inflammation/Immunology
    Palmitoyl serinol (N-Palmitoyl serinol) is an analog of the endocannabinoid N-palmitoyl ethanolamine (PEA). Palmitoyl serinol improves the epidermal permeability barrier in both normal and inflamed skin .
    Palmitoyl serinol
  • HY-P9905
    Cetuximab
    35+ Cited Publications

    C225

    Radionuclide-Drug Conjugates (RDCs) EGFR Cancer
    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
    Cetuximab
  • HY-U00002

    VEGFR EGFR Cancer
    ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.
    ZD-4190
  • HY-E70454

    Neuronal Transglutaminase; TGy; TG6

    Biochemical Assay Reagents Others
    Human epidermal transglutaminase (Neuronal Transglutaminase) is a transglutaminase. Enzymes have high catalytic efficiency, high specificity, and mild operating conditions. It can be applied in industries such as pharmaceuticals, industrial production, food manufacturing, and aquaculture .
    Human neuronal transglutaminase
  • HY-164527

    Src FAK EGFR Cancer
    Si306 is a Src inhibitor with antitumor activity. Si306 reduces the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), and inhibits the invasion of human glioblastoma (GBM) .
    Si306
  • HY-N14173

    Antibiotic Fungal Infection
    Epiderstatin is a glutarimide antibiotic. Epiderstatin has the activity of inhibiting the filamentous division induced by epidermal growth factor (EGF), but does not inhibit EGF-receptor kinase. Epiderstatin has only weak antifungal activity and no antibacterial effect .
    Epiderstatin
  • HY-162099

    EGFR Cancer
    VEGFR-IN-4 (Compound 6e) is an epidermal growth factor receptor (EGFR) inhibitor. VEGFR-IN-4 has potent antiproliferative activity with an IC50 value of 24.6nM against HCC827 cells .
    VEGFR-IN-4
  • HY-155189

    Melanocortin Receptor Others
    IIIM-8 is a melanogenesis inhibitor. IIIM-8 inhibits pigment production both in vitro and in vivo without incurring any cytotoxicity in Human Adult Epidermal Melanocytes (HAEM). IIIM-8 can be used for hyperpigmentation disorders research .
    IIIM-8
  • HY-P10697

    LDLR Metabolic Disease
    VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .
    VH4127
  • HY-100214

    EGFR Cancer
    EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFR L858R/T790M. EAI001 can be used for research of cancer .
    EAI001
  • HY-N8473

    (+)-Pericosine A

    Topoisomerase Cancer
    Pericosine A ((+)-Pericosine A) is a topoisomerase II (Topoisomerase II) inhibitor that can be isolated from the Periconia byssoides strain. Pericosine A has significant antitumor activity in vitro and in vivo and can be used in cancer research. Pericosine A also inhibits the protein kinase epidermal growth factor receptor .
    Pericosine A
  • HY-125407S

    N-Palmitoyl serinol-d5

    Cannabinoid Receptor Inflammation/Immunology
    Palmitoyl serinol-d5 is the deuterium labeled Palmitoyl serinol[1]. Palmitoyl serinol (N-Palmitoyl serinol) is an analog of the endocannabinoid N-palmitoyl ethanolamine (PEA). Palmitoyl serinol improves the epidermal permeability barrier in both normal and inflamed skin[2][3].
    Palmitoyl serinol-d5
  • HY-P1799

    Phosphatase Others
    [pTyr5] EGFR (988-993) is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .
    [pTyr5] EGFR (988-993)
  • HY-114456

    Insulin Receptor Metabolic Disease
    Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia .
    Ganglioside GM3
  • HY-19909

    EGFR Cancer
    NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist with anti-cancer and anti-proliferative properties. NRC-2694 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NRC-2694
  • HY-18764

    PTEN Metabolic Disease
    BpV(pic) potassium hydrate is a PTEN inhibitor with IC50 31 nM. BpV(pic) potassium hydrate is also an insulin simulator that activates insulin receptor kinase in cultured liver cancer cells, stimulates adipogenesis in adipocytes, and inhibits the dephosphorylation of autophosphorylated insulin receptors and epidermal growth factor receptors in rat hepatosomes .
    BpV(pic) potassium hydrate
  • HY-P4669

    BPR277

    Elastase Inflammation/Immunology
    LM-030 (BPR277) is a potent kallikrein-related peptidase 7 (KLK7) and epidermal elastase 2 (ELA2) inhibitor with IC50s of 6 nM and 55 nM, respectively(Example 4) . LM-030 can be used for the study of Netherton syndrome .
    LM-030
  • HY-138916

    Biochemical Assay Reagents EGFR Others
    PF-06672131 is an alkynylated afatinib derivative and a small molecule probe that is reactive to cysteine. PF-06672131 is an inhibitor of epidermal growth factor receptor (EGFR) kinase that targets the ATP pockets of EGFR. PF-06672131 can be used for activity-based protein profiling studies .
    PF-06672131
  • HY-P9985
    Disitamab vedotin
    2 Publications Verification

    RC48

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity .
    Disitamab vedotin
  • HY-114667

    EGFR Others
    Lavendustin C6 is a specific inhibitor of tyrosine kinase. Lavendustin C6 inhibits epidermal growth factor (EGF) receptor tyrosine kinase with an EC50 value of 0.05 μg/mL. Lavendustin C6 inhibits platelet-derived growth factor (PDGF)-induced inositol phosphate formation .
    Lavendustin C6
  • HY-P1799A

    Phosphatase Others
    [pTyr5] EGFR (988-993) TFA is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) TFA is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .
    [pTyr5] EGFR (988-993) (TFA)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: